Kapma Marten R, Groen Henk, Oranen Bjorn I, van der Hilst Christian S, Tielliu Ignace F, Zeebregts Clark J, Prins Ted R, van den Dungen Jan J, Verhoeven Eric L
Department of Surgery, University Medical Center Groningen, University of Groningen, The Netherlands.
J Endovasc Ther. 2007 Dec;14(6):777-84. doi: 10.1583/07-2182.1.
To assess mortality and treatment costs of a new management protocol with preferential use of emergency endovascular aneurysm repair (eEVAR) for acute abdominal aortic aneurysm (AAA).
From September 2003 until February 2005, 49 consecutive patients (45 men; mean age 71 years) with acute AAA were entered into a prospective study of a new management protocol that featured preferential use of eEVAR (n=18); patients with unsuitable anatomy or who were hemodynamically unstable underwent open repair (n=31). Mortality data and costs of treatment were compared in this mixed prospective group to a historical control group consisting of 147 patients (128 men; mean age 71 years) who underwent open repair from January 1998 to December 2001. All direct medical costs were included from the moment of admission until discharge from the hospital.
Mortality in the mixed prospective group (18%) was lower than in the historical control group (31%), but the difference did not reach statistical significance (p=0.099). The mean total cost in the mixed prospective group was 17,164 euro compared to 21,084 euro in the historical open repair group (p=0.255).
A preferential eEVAR protocol for acute AAA can decrease mortality and does not increase overall costs during initial treatment, but larger studies are needed to determine if these trends are statistically significant.
评估一种新的管理方案的死亡率和治疗成本,该方案优先使用急诊血管内动脉瘤修复术(eEVAR)治疗急性腹主动脉瘤(AAA)。
从2003年9月至2005年2月,49例连续的急性AAA患者(45例男性;平均年龄71岁)进入一项新管理方案的前瞻性研究,该方案的特点是优先使用eEVAR(n = 18);解剖结构不合适或血流动力学不稳定的患者接受开放修复(n = 31)。将这个混合前瞻性组的死亡率数据和治疗成本与一个历史对照组进行比较,该历史对照组由1998年1月至2001年12月接受开放修复的147例患者(128例男性;平均年龄71岁)组成。从入院到出院的所有直接医疗成本都被纳入。
混合前瞻性组的死亡率(18%)低于历史对照组(31%),但差异未达到统计学显著性(p = 0.099)。混合前瞻性组的平均总成本为17,164欧元,而历史开放修复组为21,084欧元(p = 0.255)。
急性AAA的优先eEVAR方案可降低死亡率,且在初始治疗期间不会增加总体成本,但需要更大规模的研究来确定这些趋势是否具有统计学显著性。